<DOC>
	<DOCNO>NCT02687035</DOCNO>
	<brief_summary>The purpose trial determine safety effectiveness Edwards Edwards SAPIEN 3 transcatheter heart valve delivery system intend use patient symptomatic , calcific , severe aortic stenosis .</brief_summary>
	<brief_title>The PARTNER II Trial : S3iCAP</brief_title>
	<detailed_description>This multi-center , single arm registry provide continued access Edwards SAPIEN 3 Transcatheter Heart Valve delivery system severe aortic stenosis patient intermediate risk standard aortic valve replacement . Patient data enter TVT Registry ( TVTR ) screen 1 year include collection 5 year follow-up CMS .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patients must cover Medicare . This enable Edwards link CMS database long term followup 5 year . No insurance provider accept . 2 . Assessment intermediate surgical risk define STS 48 % heart team assessment intermediate risk factor . 3 . Patient senile degenerative aortic valve stenosis echocardiographically derive criterion : mean gradient &gt; 40 mmHg jet velocity great 4.0 m/s initial aortic valve area ( AVA ) &lt; 0.8 cm2 indexed EOA &lt; 0.5 cm2/m2 . Qualifying echo must within 60 day date procedure . 4 . Aortic valve annulus area range ( 273mm2680 mm2 ) per 3D imaging ( echo , CT , MRI ) . 5 . Patient symptomatic his/her aortic valve stenosis , demonstrate NYHA Functional Class II great . 6 . The heart team agree ( verified case review process ) valve implantation likely benefit patient . 7 . Heart team agree ( priori ) treatment strategy concomitant coronary disease ( present ) . 8 . The study patient study patient 's legal representative inform nature study , agree provision provide write informed consent approve Institutional Review Board ( IRB ) respective clinical site . 9 . The study patient agree comply required postprocedure followup visit include annual visit 5 year analysis close date visit , conduct phone followup . 1 . Heart team assessment inoperability ( include examine cardiac surgeon ) . 2 . Evidence acute myocardial infarction ≤ 1 month ( 30 day ) intend treatment [ ( define : Q wave MI , nonQ wave MI total CK elevation CKMB ≥ twice normal presence MB elevation and/or troponin level elevation ( WHO definition ) ] . 3 . Aortic valve congenital unicuspid congenital bicuspid valve , noncalcified . 4 . Mixed aortic valve disease ( aortic stenosis aortic reregurgitation predominant aortic regurgitation &gt; 3+ ) . 5 . Preexisting mechanical bioprosthetic valve position . 6 . Complex coronary artery disease : 1 . Unprotected leave main coronary artery 2 . Syntax score &gt; 32 ( absence prior revascularization ) 7 . Any therapeutic invasive cardiac procedure result permanent implant perform within 30 day index procedure ( unless part plan strategy treatment concomitant coronary artery disease ) . Implantation permanent pacemaker ICD consider exclusion criterion . 8 . Any patient balloon valvuloplasty ( BAV ) &lt; 30 day procedure ( unless BAV bridge procedure qualify ECHO ) . 9 . Patients plan concomitant surgical transcatheter ablation atrial fibrillation . 10 . Leukopenia ( WBC &lt; 3000 cell/mL ) , acute anemia ( Hgb &lt; 9 g/dL ) , thrombocytopenia ( Plt &lt; 50,000 cell/mL ) . 11 . Hypertrophic cardiomyopathy without obstruction ( HOCM ) . 12 . Hemodynamic respiratory instability require inotropic support , mechanical ventilation mechanical heart assistance within 30 day screen evaluation . 13 . Need emergency surgery reason . 14 . Severe ventricular dysfunction LVEF &lt; 20 % . 15 . Echocardiographic evidence intracardiac mass , thrombus vegetation . 16 . Active upper GI bleeding within 3 month ( 90 day ) prior procedure . 17 . A known contraindication hypersensitivity anticoagulation regimen , inability anticoagulated study procedure . 18 . Native aortic annulus size &lt; 16 mm &gt; 28mm measure echocardiogram . 19 . Clinically ( neurologist ) neuroimaging confirm stroke transient ischemic attack ( TIA ) within 6 month ( 180 day ) procedure . 20 . Renal insufficiency ( creatinine &gt; 3.0 mg/dL ) and/or renal replacement therapy time screen . 21 . Estimated life expectancy &lt; 24 month ( 730 day ) due carcinoma , chronic liver disease , chronic renal disease chronic end stage pulmonary disease . 22 . Expectation patient improve despite treatment aortic stenosis . 23 . Significant aortic disease , include mark tortuosity ( hyperacute bend ) , aortic arch atheroma [ especially thick ( &gt; 5 mm ) , protrude ulcerated ] narrowing ( especially calcification surface irregularity ) abdominal thoracic aorta , severe `` unfolding '' tortuosity thoracic aorta . ( Transfemoral ) 24 . Iliofemoral vessel characteristic would preclude safe placement 14F 16F introducer sheath severe obstructive calcification , severe tortuosity minimum average vessel size le 5.5 mm . ( Transfemoral ) . 25 . Currently participate investigational drug another device study . Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial . 26 . Active bacterial endocarditis within 6 month ( 180 day ) procedure . 27 . Evidence intracardiac mass , thrombus , vegetation , active infection endocarditis . 28 . Inability tolerate anticoagulation/antiplatelet therapy . 29 . For transfemoral approach : Femoroiliac vessel &lt; 5.5 mm 23 mm 26 mm system &lt; 6.0 mm 29 mm system .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>S3iCAP</keyword>
	<keyword>SAPIEN 3</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>Commander</keyword>
	<keyword>Certitude</keyword>
	<keyword>TAVR</keyword>
	<keyword>TAVI</keyword>
	<keyword>Aortic stenosis</keyword>
	<keyword>THV</keyword>
	<keyword>Transcatheter Heart Valve</keyword>
	<keyword>TVT</keyword>
	<keyword>TVTR</keyword>
</DOC>